- Bevacizumab and oral metronomic cyclophosphamide in platinum-resistant ovarian cancer
-
Pujade-Lauraine E
- KMID: 2288525
- J Gynecol Oncol.
- 2013 Jul;24(3):209-211.
- doi: 10.3802/jgo.2013.24.3.209
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Olaparib plus bevacizumab as maintenance therapy in patients with newly diagnosed, advanced ovarian cancer: Japan subset from the PAOLA-1/ENGOT-ov25 trial
-
Fujiwara K, Fujiwara H, Yoshida H, Satoh T, Yonemori K, Nagao S, Matsumoto T, Kobayashi H, Bourgeois H, Harter P, Mosconi AM, Vazquez IP, Reinthaller A, Fujita T, Rowe P, Pujade-Lauraine E, Ray-Coquard I
- KMID: 2526133
- J Gynecol Oncol.
- 2021 Sep;32(5):e82.
- doi: 10.3802/jgo.2021.32.e82
Objective The addition of maintenance olaparib to bevacizumab demonstrated a significant progression-free survival (PFS) benefit in patients with newly diagnosed, advanced ovarian cancer in the PAOLA-1/ENGOT-ov25 trial (NCT02477644). We evaluated maintenance... -
- CITED
-
- Close
- SHARE
-
- Close
- Update on rare epithelial ovarian cancers: based on the Rare Ovarian Tumors Young Investigator Conference
-
Jang JY, Yanaihara , Pujade-Lauraine E, Mikami Y, Oda K, Bookman M, Ledermann , Shimada M, Kiyokawa T, Kim BG, Matsumura , Kaku T, Kuroda T, Nagayoshi , Kawabata A, Iida Y, Kim JW, Quinn M, Okamoto A
- KMID: 2413437
- J Gynecol Oncol.
- 2017 Jul;28(4):e54.
- doi: 10.3802/jgo.2017.28.e54
There has been significant progress in the understanding of the pathology and molecular biology of rare ovarian cancers, which has helped both diagnosis and treatment. This paper provides an update... -
- CITED
-
- Close
- SHARE
-
- Close
